0
Abstract: Poster Presentations |

LONG-TERM SAFETY AND EFFICACY OF NEBULIZED ARFORMOTEROL IN SUBJECTS WITH COPD FREE TO VIEW

Nicola Hanania, MD*; James Donohue, MD; Harold Nelson, MD; Kenneth Sciarappa, PhD; Elizabeth Goodwin, PhD; Rudolf Baumgartner, MD; John Hanrahan, MD
Author and Funding Information

Baylor College of Medicine, Houston, TX


Chest


Chest. 2008;134(4_MeetingAbstracts):p106001. doi:10.1378/chest.134.4_MeetingAbstracts.p106001
Text Size: A A A
Published online

Abstract

PURPOSE:The long-term safety and efficacy of two long-acting β2-agonists (LABAs) arformoterol (administered via nebulization) and racemic formoterol DPI were compared in subjects with COPD in a multi-center, 6-month randomized, double-blind, double-dummy clinical trial.

METHODS:COPD subjects (mean FEV1 1.21 L, ∼41.0 % predicted) were randomized to receive either nebulized arformoterol (15μg BID [n=149]: 25μg BID [n=147]) or formoterol (12μg BID [n=147]). The primary endpoint was frequency of adverse events (AEs). Secondary endpoints included evaluation of pulmonary function and use of rescue medication.

RESULTS:The frequency of any adverse event for arformoterol 15 μg BID, 25 μg BID and racemic formoterol DPI 12 μg BID were 67.8%, 76.2% and 66.7%, respectively. The cumulative frequency of serious adverse events (SAEs) were 13.4%, 6.8%, and 9.5%, respectively, and 6.0%, 2.7%, and 4.1% for respiratory SAEs. Study discontinuations due to an AE occurred in 10.1%, 10.9%, and 8.2% of subjects in the 3 treatment groups, respectively. COPD exacerbations occurred in 31.5%, 29.3% and 22.4% of subjects, respectively. In all groups, exacerbations occurred with less frequency after 3- to 6-months of treatment compared with the first 3-months. Following the first study dose, mean FEV1AUC0–6 improved significantly from baseline for all treatment groups (arformoterol 15μg: 19.4%, 25 μg: 23.1%, formoterol: 16.9%). This improvement was sustained at 6-months (18.8%, 22.5%, and 16.2%; respectively). The 24-hour trough FEV1 also improved significantly for all treatment groups both after first dose (arformoterol 15μg: 14.9%, 25μg: 14.4%, formoterol: 14.1%) and at 6-months (10.2%, 13.4%, and 10.1%, respectively). Similarly, peak FEV1 improved significantly from baseline post-first dose (range: 26.3% to 32.3%), increases that were sustained at 6-months (range: 25.7% to 31.6%). Use of the short acting bronchodilators ipratropium and albuterol demonstrated significant decreases of -0.8 to -1.3 actuations/day for each of the treatments and remained stable over the entire 6-months.

CONCLUSION:In this study, all LABA treatments were well-tolerated, improved pulmonary function, and reduced short-acting inhaled bronchodilator use over 6-months.

CLINICAL IMPLICATIONS:Arformoterol and formoterol are effective maintenance bronchodilators in COPD subjects.Study supported by Sepracor Inc.

DISCLOSURE:Nicola Hanania, Consultant fee, speaker bureau, advisory committee, etc. Dr. Hanania participated in an Advisory Board meeting sponsored by Sepracor Inc.; No Product/Research Disclosure Information

Wednesday, October 29, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543